

FORM PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
P28604Application No.  
10/551,780INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)Applicant  
Motoharu SEIKI et al.Filing Date  
October 3, 2005Group  
1642

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPRO.)
	2005/0074499 A1	05/07/05	TAGAWA, et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	98/22092 A1	05/28/98	WO				
	1 170 018 A1	01/09/02	EP				
	93/25255 A1	12/23/93	WO				

## OTHER DOCUMENTS

	DOCUMENT (Including Author, Title, Date, Pertinent Pages, Etc.)
	Supplementary European Search Report issued in counterpart European application No. 04 72 5481, dated August 27, 2010.
	Lundberg et al., "Conjugation of an Anti-B-Cell Lymphoma Monoclonal Antibody. LL2, to Long-Circulating Drug-Carrier Lipid Emulsions", Journal of Pharmacy and Pharmacology, Royal Pharmaceutical Society of Great Britain, Vol. 51, No. 10, January 1, 1999, pages 1099-1105.
	Maruyama, "PED-Immunoliposome", Bioscience Reports, Springer, New York, US, Vol. 22, No. 2, April 1, 2002, pages 251-266.

EXAMINER

/Mark Halvorson/

DATE CONSIDERED

06/28/2011

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/